Monitor for Form 144 filings or 10b5-1 plan disclosures; this volume of derivative exercise and sale may indicate a planned liquidity event rather than negative sentiment. No material fundamental change is implied.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 27 $501.29entry
- T+1 · 9mo ago +1.90%α +1.85% · $510.82
- T+5 · 9mo ago −5.14%α −3.16% · $475.52
- T+20 · 8mo ago +4.29%α +11.84% · $522.78
- T+60 · 6mo ago +15.39%α +6.00% · $578.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics CEO Martine Rothblatt and several insiders engaged in a series of derivative exercises and open-market sales over a 3-day period, including $1.39M in open-market share sales by Rothblatt and $2.8M in derivative exercises at non-zero cost. The activity is part of a structured transaction plan, not opportunistic selling.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 9,779 shares in open market for $1.52M across two transactions on March 3 and March 5, 2026.
- Rothblatt exercised 38,000 derivative securities in total, with $2.77M of those exercises at $146.03 per share (cash-out or cashless exercise).
- Other insiders (EVP, directors) exercised derivatives totaling $1.92M in value at non-zero cost, with additional non-cash exercises (tax withholding or awards).
- Total open-market sales in cluster: $1.55M (Rothblatt $1.52M, Malcolm Jan $25,460).
- Total derivative exercises with cash cost: $4.69M (Rothblatt $2.77M, Mahon $1.21M, Kurzweil $0.50M, Thompson $0.20M, Causey $2.4K).
- All transactions occurred between March 3–5, 2026, suggesting a coordinated, pre-arranged plan.
Financial Impact
$1.55M in open-market sales and $4.69M in cash-backed derivative exercises over 3 days
Risk Factors
- Perception of insider selling pressure despite structured nature
- Potential for short-term price sensitivity if retail interprets sales as bearish
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (16 trades, 7d window) | cluster-UTHR-1773088594190 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers